Exiscientia to raise $100 million in a series C deal backed by BlackRock

Exscientia, a London, UK-based clinical stage pharmatech, announced closing Series C investment round that totalled $100 million in funding.

The money was raised from funds managed by BlackRock and included contributions from existing Series C investors, Novo Holdings, Evotec, Bristol Myers Squibb, and GT Healthcare Capital.

Proceeds to further accelerate AI drug discovery platform and pipeline.

Exscientia, founded in 2012 by CEO Andrew Hopkins, developed an end-to-end AI-first drug discovery platform, that makes it possible to generate novel drugs and overcome conventional drug discovery limitations several years faster than industry benchmarks. In addition to its growing proprietary pipeline, the company has conducted drug discovery partnerships with Bristol-Myers Squibb, Sanofi, Bayer and Dainippon Sumitomo as well as several biotech companies.